Overall Risk of Moderate OSA
Moderate obstructive sleep apnea (AHI 15-29.9 events/hour) significantly increases mortality and cardiovascular risk, with a 56% increased risk of cardiovascular events and approximately 2.5-fold increased risk of all-cause mortality compared to those without OSA.
Mortality Risk
The most recent high-quality evidence demonstrates that moderate OSA independently predicts death. A 2026 prospective cohort study of 2,401 patients followed for 6 years found that OSA with respiratory event index (REI) ≥15 was independently associated with all-cause mortality (HR 2.65; 95% CI 1.12-6.30) 1. The study showed a progressive, dose-dependent increase in mortality risk across OSA severity categories, with moderate OSA (REI 15-29.9) falling in the middle of this continuum 1.
A 2025 meta-analysis of prospective cohort studies involving over 25,000 participants confirmed this severity-dependent pattern, reporting moderate OSA carries an HR of 1.56 (95% CI 1.20-2.03) for cardiovascular events 2. This risk is substantially lower than severe OSA (HR 2.45) but meaningfully elevated compared to mild OSA (HR 1.21) 2.
Age-Dependent Risk Modification
The mortality risk from moderate OSA is dramatically higher in younger adults (<60 years) compared to older adults. A 2024 Penn State Adult Cohort study of 1,681 adults followed for 20 years revealed that mild-to-moderate OSA significantly increased mortality in those under 60 years (HR 1.59,95% CI 1.08-2.04) but showed no significant association in those ≥60 years (HR 1.05,95% CI 0.80-1.39) 3. This suggests that age-based treatment thresholds may be warranted, with more aggressive intervention justified in younger patients with moderate OSA.
Cardiovascular Disease Risk
Moderate OSA confers specific cardiovascular risks:
- Stroke risk: 2.15-fold increase (95% CI 1.42-3.24) 4
- Overall cardiovascular disease: 1.56-fold increase 2
- Hypertension: 2.19-fold increase compared to mild OSA 5
- Acute coronary syndrome: Higher SYNTAX scores and 8.6% vs 3.2% MACE rate compared to controls over 30 months 6
The 2013 meta-analysis found that each 10-unit increase in AHI was associated with a 17% greater risk of cardiovascular disease 4.
Metabolic Complications
Moderate-to-severe OSA increases metabolic syndrome risk by 2.18-fold compared to mild OSA (OR 2.18,95% CI 1.30-3.68), based on a 2026 meta-analysis of 10,205 participants 5. Specific metabolic risks include:
- Hyperglycemia: 1.50-fold increased risk 5
- Hypertension: 2.19-fold increased risk 5
- Greater glycemic variability: Particularly in patients with diabetes 7
Synergistic Risk with Comorbidities
The presence of comorbid conditions dramatically amplifies moderate OSA risk:
- Comorbid insomnia (COMISA): Triples mortality risk (HR 3.02; 95% CI 1.30-7.04) compared to OSA alone 1
- Cardiovascular/cerebrovascular disease: Creates synergistic effect with 3.82-fold mortality increase in those <60 years 3
- Hypertension: Additive effect with moderate OSA in younger adults 3
Clinical Implications from Guidelines
The 2013 American College of Physicians guideline acknowledges that while treatment assessment focuses primarily on daytime sleepiness improvement, "the effect on other clinical outcomes, including hypertension, cardiovascular events, and death, is uncertain" 8. However, this guideline predates the robust mortality and cardiovascular outcome data from 2024-2026 studies.
The 2026 Chinese guidelines recommend PAP therapy for moderate OSA (AHI ≥15 events/h) as first-line treatment and suggest considering treatment even for mild OSA when cardiovascular disease, cerebrovascular disease, hypertension, or diabetes are present 9.
Treatment Impact on Risk
Adequate CPAP adherence (≥4 hours/night) reduces cardiovascular risk by 24% (HR 0.76,95% CI 0.60-0.96) 2. This risk reduction underscores that moderate OSA is a modifiable risk factor when properly treated.
Key Clinical Pitfalls
- Don't dismiss moderate OSA in younger patients: The mortality risk is highest in those <60 years and may warrant more aggressive treatment 3
- Screen for comorbid insomnia: COMISA triples mortality risk and requires specific management 1
- Consider cardiovascular comorbidities: Even mild-to-moderate OSA becomes high-risk in the presence of cardiovascular/cerebrovascular disease 3
- Don't rely solely on symptoms: Asymptomatic moderate OSA still carries significant cardiovascular and metabolic risk 9